Literature DB >> 9192833

Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells.

B W Cherney1, K G Bhatia, C Sgadari, M I Gutierrez, H Mostowski, S E Pike, G Gupta, I T Magrath, G Tosato.   

Abstract

Burkitt's lymphoma (BL) cell lines carry a translocated c-myc gene and, in 60-80% of cases, exhibit mutations in the p53 tumor suppressor gene. We examined the potential role of the p53 gene in BL tumorigenicity using an in vitro assay that measures p53-dependent cell cycle arrest in the G1 phase of the cell cycle and an in vivo athymic murine model that detects differences in the tumorigenicity of BL cell lines. A highly significant inverse correlation was found between the ability of BL cells to arrest in G1 after irradiation and their tumorigenicity in athymic mice, consistent with the notion that loss of p53 function is associated with increased tumorigenicity. Inactivation of wild-type (wt) p53 function by expression of the human papillomavirus E6 protein in the AG876V BL cell line, which carries both wt and mutant p53 proteins, rendered the cell line significantly more tumorigenic in athymic mice. Transfection of the wt p53 gene into the p53 mutant and highly tumorigenic BL-41 cell line caused it to acquire wt p53 function and rendered it less tumorigenic in mice. In addition to confirming a role for the loss of p53 function in tumor progression, the data demonstrate that wt p53 protein can reduce BL tumorigenicity in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192833

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.

Authors:  Ana Carolina Dos Santos Ferreira; Renan Amphilophio Fernandes; Jolie Kiemlian Kwee; Claudete Esteves Klumb
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-01       Impact factor: 4.553

2.  Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis.

Authors:  Emily E Bosco; Wenjun Ni; Lei Wang; Fukun Guo; James F Johnson; Yi Zheng
Journal:  Blood       Date:  2010-02-23       Impact factor: 22.113

3.  Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents.

Authors:  Z Lin; S Lim; M A Viani; M Sapp; M S Lim
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

4.  Wild-type TP53 defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs.

Authors:  Chen Zhang; Emmanuel Martinez-Ledesma; Feng Gao; Wei Zhang; Jie Ding; Shaofang Wu; Xiaolong Li; Jimin Wu; Ying Yuan; Dimpy Koul; W K Alfred Yung
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

Review 5.  Epstein-Barr virus and Burkitt lymphoma.

Authors:  G Brady; G J MacArthur; P J Farrell
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

6.  An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas.

Authors:  Katrina K Hoyer; Mabel Pang; Dorina Gui; I Peter Shintaku; Ichiro Kuwabara; Fu-Tong Liu; Jonathan W Said; Linda G Baum; Michael A Teitell
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

7.  Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth.

Authors:  S E Pike; L Yao; K D Jones; B Cherney; E Appella; K Sakaguchi; H Nakhasi; J Teruya-Feldstein; P Wirth; G Gupta; G Tosato
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

Review 8.  How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma?

Authors:  Martin J Allday
Journal:  Semin Cancer Biol       Date:  2009-07-25       Impact factor: 15.707

Review 9.  EBV and Apoptosis: The Viral Master Regulator of Cell Fate?

Authors:  Leah Fitzsimmons; Gemma L Kelly
Journal:  Viruses       Date:  2017-11-13       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.